As Ligand Pharmaceuticals Incorporated (LGND) Valuation Rose, Shareholder Knott David M Has Lowered by $27.20 Million Its Stake

January 19, 2018 - By Marie Mckinney

Investors sentiment increased to 1.69 in 2017 Q3. Its up 0.45, from 1.24 in 2017Q2. It increased, as 19 investors sold LGND shares while 68 reduced holdings. 50 funds opened positions while 97 raised stakes. 22.76 million shares or 0.86% more from 22.57 million shares in 2017Q2 were reported. Citigroup has invested 0% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). State Of Alaska Department Of Revenue reported 4,137 shares. Fortaleza Asset Mgmt holds 0.36% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 1,445 shares. Goldman Sachs Gp reported 265,683 shares. Prudential Fin has 72,150 shares for 0.02% of their portfolio. Vanguard Incorporated holds 0.01% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 1.77M shares. 35,124 were reported by Timpani Cap Mngmt Ltd. Raymond James And Associate holds 8,752 shares or 0% of its portfolio. White Pine Capital Ltd Com accumulated 0% or 7,158 shares. Thrivent For Lutherans reported 0.01% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Suntrust Banks Inc stated it has 0% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). First Republic Invest Incorporated invested 0.01% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Granite Invest Prtnrs Limited Liability owns 117,396 shares. Australia-based Macquarie Limited has invested 0.11% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). 2,556 are owned by Intrust Financial Bank Na.

Since August 8, 2017, it had 0 buys, and 7 selling transactions for $5.22 million activity. Aryeh Jason had sold 2,000 shares worth $255,980 on Wednesday, August 23. 6,100 shares were sold by FOEHR MATTHEW W, worth $777,824. 925 shares valued at $126,956 were sold by Sabba Stephen L on Wednesday, December 20. $362,500 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares were sold by KOZARICH JOHN W. $2.36M worth of stock was sold by Berkman Charles S on Wednesday, August 9.

Knott David M decreased its stake in Ligand Pharmaceuticals Incorporated (LGND) by 20.04% based on its latest 2017Q3 regulatory filing with the SEC. Knott David M sold 200,000 shares as the company’s stock rose 7.66% with the market. The institutional investor held 798,100 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $108.66 million, down from 998,100 at the end of the previous reported quarter. Knott David M who had been investing in Ligand Pharmaceuticals Incorporated for a number of months, seems to be less bullish one the $3.23 billion market cap company. The stock increased 1.61% or $2.42 during the last trading session, reaching $152.98. About 118,132 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has declined 2.87% since January 19, 2017 and is downtrending. It has underperformed by 19.57% the S&P500.

Analysts await Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report earnings on February, 22. They expect $0.92 EPS, up 713.33 % or $1.07 from last year’s $-0.15 per share. LGND’s profit will be $19.42M for 41.57 P/E if the $0.92 EPS becomes a reality. After $0.55 actual EPS reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts 67.27 % EPS growth.

More news for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) were recently published by: Streetinsider.com, which released: “Form 8-K LIGAND PHARMACEUTICALS For: Dec 26” on December 26, 2017. Investorplace.com‘s article titled: “5 Big Biotech Stocks To Buy In 2018” and published on January 17, 2018 is yet another important article.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings Coverage

Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Ligand Pharmaceuticals had 23 analyst reports since September 3, 2015 according to SRatingsIntel. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Overweight” rating given on Wednesday, April 13 by Stephens. The rating was maintained by Craig Hallum on Wednesday, November 15 with “Buy”. Deutsche Bank maintained it with “Hold” rating and $103 target in Monday, July 17 report. As per Wednesday, September 30, the company rating was maintained by TH Capital. H.C. Wainwright maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Thursday, October 5 with “Buy” rating. The rating was maintained by Roth Capital with “Buy” on Wednesday, October 11. The rating was downgraded by Deutsche Bank to “Sell” on Monday, November 20. H.C. Wainwright maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) rating on Thursday, November 9. H.C. Wainwright has “Buy” rating and $159 target. Roth Capital maintained the shares of LGND in report on Thursday, September 3 with “Buy” rating. TH Capital maintained the stock with “Buy” rating in Friday, December 18 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.